Sinemet Information
What's inside Sinemet
Sinemet Active Ingredients: carbidopa, levodopa, details.| Sinemet Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Sinemet 25 mg-250 mg | tablet | oral | 1.0 each | OTC |
| Sinemet 25 mg-250 mg | tablet | oral | 1.0 each | OTC |
| Sinemet 25 mg-100 mg | tablet | oral | 1.0 each | OTC |
| Sinemet 10 mg-100 mg | tablet | oral | 1.0 each | OTC |
Recent Sinemet Side Effects
Posted by cbbb4347 over 7 years ago
I need to know what the side effects are for this medication.
Sinemet in the News
High blood pressure? Try beet juice - Youngstown Vindicator
I have used Sinemet and Mirapex separately during the past eight years, but stopped each due to side effects. I am currently unmedicated and miserable. ...
Thu Feb 28 00:11:45 -0500 2008
Posted By susanna mcleod - The Kingston Whig-Standard
But Sinemet, a medication to alleviate her Parkinson-like symptoms, caused horrific hallucinations when the dose was off by the slightest bit. ...
Thu Jan 31 05:53:36 -0500 2008
Jane Music faced painful decision as husband's Alzheimer's worsened - Louisville Courier-Journal
With therapy, medication changes including a Parkinson's drug called Sinemet and Jane's daily visits, Houghton saw steady improvements, especially in ...
Sun Jan 13 05:48:29 -0500 2008
Sinemet Chemical Information
carbidopa - A hydrazine derivative of dopa. Carbidopa is a peripheral dopa decarboxylase inhibitor that is used as an adjunct to levodopa administration to prevent peripheral biosynthesis of levodopa to dopamine, thereby reducing peripheral side effects. Carbidopa does not penetrate the blood brain barrier so that levodopa, after it reaches the brain, can be metabolized to dopamine by dopa decarboxylase where it exerts its effect on dopamine receptors.
levodopa - An amino acid precursor of dopamine with antiparkinsonian properties. Levodopa is a prodrug that is converted to dopamine by DOPA decarboxylase and can cross the blood-brain barrier. When in the brain, levodopa is decarboxylated to dopamine and stimulates the dopaminergic receptors, thereby compensating for the depleted supply of endogenous dopamine seen in Parkinson's disease. To assure that adequate concentrations of levodopa reach the central nervous system, it is administered with carbidopa, a decarboxylase inhibitor that does not cross the blood-brain barrier, thereby diminishing the decarboxylation and inactivation of levodopa in peripheral tissues and increasing the delivery of dopamine to the CNS.
Sinemet RSS Feed
